CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
2024 highlights the most tax-efficient Dividend Etfs and the factors behind their efficiency, helping you pick better tax-smart options.
24,637 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Medicare is tightening oversight on hospice providers amid rising admissions and fraud concerns. The crackdown could ...
A small group of everyday investors rode space-data trends to multimillion-dollar gains years before a SpaceX IPO hea...
Wingstop topped Q4 expectations, delivering a key earnings beat while expanding its restaurant base. The dual story: ...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Trading activity in the largest non-stablecoin crypto assets cooled to two-year lows as investors sit on the sideline...
Meta just made striking moves in AI infrastructure that could tilt demand in Nvidia's favor. This deep dive explains ...
Megapot has secured $5 million in a Dragonfly-led round to scale a crypto-powered global lottery. The platform now se...
Brinker International is moving from a multi-year tech upgrade to an AI-focused growth plan across Chili’s and Maggia...
Hims & Hers Health fell after guiding Q1 2026 revenue below expectations, citing a $65 million headwind from regulato...
Federal investigators say UCLA's David Geffen School of Medicine used race in admissions in ways that violated civil ...
ADA sinks toward its latest lows as the broader crypto sell-off deepens. With Hoskinson’s cautions and liquidity fadi...